ClinicalTrials.gg
Active, not recruitingNCT07791342Updated Aug 27, 2026

A Phase I Study of 9MW4113 Injection Versus Dupixent®

A Phase 1 interventional study of 9MW4113 injection and Dupilumab in Healthy Participants, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2026, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

It is a randomized, double-blinded, parallel, single-dose, Phase I comparative study to evaluate the pharmacokinetic, safety, and immunogenicity similarity between 9MW4113 and Dupixent® in healthy Chinese adult participants. A total of 208 healthy participants are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml 9MW4113 injection or Dupixent®.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who fully understand the study objectives, nature, methods, and possible adverse reactions, volunteer to participate, and sign the ICF before any study-related procedures begin.
  2. Chinese healthy participants aged 18 to 50 years, inclusive.
  3. Body weight between 55 and 85kg, inclusive, between 19.0 and 28.0kg/m2, inclusive.
  4. Normal vital signs, physical examination, clinical laboratory test results, and other ancillary examination findings, or abnormalities considered not by the investigator.
  5. Female participants who are not planning to become pregnant and who agree to use adequate from 2 weeks prior to screening to 6 months after dosing.
  6. Participants able to communicate well with the investigator and able to understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history of specific allergies or with allergic diathesis (e.g., allergy to two or more drugs or foods).
  2. Known to any component of the product or to other similar biological products, especially monoclonal antibodies.
  3. Presence of active tuberculosis infection as revealed by chest X-ray at screening.
  4. ≥ 5% change (increase or decrease) in body weight at Day -1 (pre-randomization) versus screening.
  5. History of chronic or significant diseases involving the cardiovascular, digestive, genitourinary, respiratory, hematologic, endocrine, immune, psychiatric/neurological, or skeletal systems.
  6. Prior treatment with a monoclonal antibody targeting the same target, or prior participation in a dupilumab clinical trial.
  7. Use of biological products within 3 months or 5 half-lives (whichever is longer) prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    9MW4113 injection

    "9MW4113 injection; 300mg/2.0mL; subcutaneous injection. This group includes 104 patients."

    Biological: 9MW4113 injection

  • Active comparator
    Dupixent®

    "Dupixent®; 300mg/2.0mL; subcutaneous injection. This group includes 104 patients."

    Biological: Dupilumab

Interventions

  • Biological9MW4113 injection

    "9MW4113 injection; 300mg/2.0mL; subcutaneous injection.

  • BiologicalDupilumab

    "Dupixent®; 300mg/2.0mL; subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics Endpoint

    Maximum Concentration (Cmax)

    Time frame: 0-9weeks

  2. Pharmacokinetics Endpoint

    Area under the concentration-time curve time 0 to infinity (AUC0-∞)

    Time frame: 0-9weeks

Secondary outcomes

  1. Pharmacokinetics Endpoint

    Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t)

    Time frame: 0-9weeks

  2. Pharmacokinetics Endpoint

    Time of maximum concentration (Tmax)

    Time frame: 0-9weeks

  3. Pharmacokinetics Endpoint

    Terminal elimination rate constant (λz)

    Time frame: 0-9weeks

  4. Pharmacokinetics Endpoint

    Terminal elimination half-life (t1/2z), t1/2z = ln2/λz

    Time frame: 0-9weeks

  5. Pharmacokinetics Endpoint

    Percentage of extrapolated area (AUC\_%Extrap), AUC\_%Extrap = \[(AUC0-∞-AUC0-t)/AUC0-∞\]×100%

    Time frame: 0-9weeks

  6. Pharmacokinetics Endpoint

    Apparent clearance (CL/F), CL/F=Dose/AUC0-∞

    Time frame: 0-9weeks

  7. Pharmacokinetics Endpoint

    Apparent volume of distribution (Vd/F) , Vd/F = (CL/F)/λz

    Time frame: 0-9weeks

  8. Safety Assessments

    adverse events, concomitant medications, concomitant non-drug therapies, injection site irritation assessment, laboratory tests (complete blood count, blood biochemistry test, urinalysis and coagulation function) clinical symptoms, vital signs , 12 lead ECGs, physical examination

    Time frame: 0-9weeks

  9. Incidence of anti-drug antibodies (ADA)

    Time frame: 0-9weeks

  10. Titer of anti-drug antibodies (ADA)

    Time frame: 0-9weeks

  11. Incidence of neutralizing antibodies (NAb)

    Time frame: 0-9weeks

07

Study locations

1 site
  • Wuhan Jinyintan Hospital(Wuhan Infectious Disease Hospital)
    Wuhan, Hubei 430023, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Jul 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 27, 2026
StartActual
Apr 22, 2026
Primary completionActual
Jul 27, 2026
CompletionEst.
Aug 17, 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07791342
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Apr 22, 2026
Primary completion
Jul 27, 2026
Completion
Aug 17, 2026 (estimated)
Last update
Aug 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion